These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
78 related articles for article (PubMed ID: 5545122)
1. Etiology of hyperparathyroidism and bone disease during chronic hemodialysis. II. Factors affecting serum immunoreactive parathyroid hormone. Fournier AE; Arnaud CD; Johnson WJ; Taylor WF; Goldsmith RS J Clin Invest; 1971 Mar; 50(3):599-605. PubMed ID: 5545122 [TBL] [Abstract][Full Text] [Related]
2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis. Brandi L Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159 [TBL] [Abstract][Full Text] [Related]
3. Effect of hypermagnesemia on circulating plasma parathyroid hormone in patients on regular hemodialysis therapy. McGonigle RJ; Weston MJ; Keenan J; Jackson DB; Parsons V Magnesium; 1984; 3(1):1-7. PubMed ID: 6482508 [TBL] [Abstract][Full Text] [Related]
4. Comparison between different dialysate calcium concentrations in nocturnal hemodialysis. Toussaint ND; Polkinghorne KR; Kerr PG; Somerville CA; Agar JW Hemodial Int; 2007 Apr; 11(2):217-24. PubMed ID: 17403174 [TBL] [Abstract][Full Text] [Related]
5. Satisfactory control of secondary hyperparathyroidism with low-calcium dialysate in patients not receiving vitamin D. Teruel JL; Nitvarro JF; Marcen R; Aguilera A; Tato A; Ottuño J Miner Electrolyte Metab; 1997; 23(1):19-24. PubMed ID: 9058365 [TBL] [Abstract][Full Text] [Related]
6. Effects of lowering dialysate calcium concentration on mineral metabolism and parathyroid hormone secretion: a multicentric study. Lezaic V; Pejanovic S; Kostic S; Pljesa S; Dimkovic N; Komadina L; Jovanovic D; Marinkovic J; Djukanovic L Ther Apher Dial; 2007 Apr; 11(2):121-30. PubMed ID: 17381533 [TBL] [Abstract][Full Text] [Related]
7. Improvement of bone and mineral parameters related to adynamic bone disease by diminishing dialysate calcium. Spasovski G; Gelev S; Masin-Spasovska J; Selim G; Sikole A; Vanholder R Bone; 2007 Oct; 41(4):698-703. PubMed ID: 17643363 [TBL] [Abstract][Full Text] [Related]
8. Etiology of hyperparathyroidism and bone disease during chronic hemodialysis. I. Association of bone disease with potentially etiologic factors. Fournier AE; Johnson WJ; Taves DR; Beabout JW; Arnaud CD; Goldsmith RS J Clin Invest; 1971 Mar; 50(3):592-8. PubMed ID: 5101783 [TBL] [Abstract][Full Text] [Related]
9. Long-term effect of different dialysate calcium concentrations on parathyroid hormone levels in hemodialysis patients. Hwang JC; Chen CA; Wang CT; Chen HC Ren Fail; 2008; 30(10):943-51. PubMed ID: 19016144 [TBL] [Abstract][Full Text] [Related]
10. Impact of lowering dialysate calcium concentration on serum bone turnover markers in hemodialysis patients. Hamano T; Oseto S; Fujii N; Ito T; Katayama M; Horio M; Imai E; Hori M Bone; 2005 May; 36(5):909-16. PubMed ID: 15794928 [TBL] [Abstract][Full Text] [Related]
12. [Influencing factors in the control of phosphorus in peritoneal dialysis. Therapeutic options]. Gallar P; Ortega O; Gutiérrez M; Muñoz M; Hilara L; Oliet A; Rodríguez I; Giménez E; Vigil A Nefrologia; 2000; 20(4):355-61. PubMed ID: 11039261 [TBL] [Abstract][Full Text] [Related]
13. Different routes bridging calcium in Japanese hemodialysis patients. Hamano T; Fujii N; Ito T; Imai E Ther Apher Dial; 2005 Feb; 9(1):32-8. PubMed ID: 15828903 [TBL] [Abstract][Full Text] [Related]
14. [Serum osteocalcin in children with chronic renal insufficiency]. Peco-Antić A; Nastić-Mirić D; Milikić V; Babić D; Pejcić I; Kostić M; Paripović V; Jovanović O; Kruscić D; Mancić J Srp Arh Celok Lek; 1996; 124(9-10):227-31. PubMed ID: 9102853 [TBL] [Abstract][Full Text] [Related]
15. Etiology of hyperparathyroidism and bone disease during chronic hemodialysis. 3. Evaluation of parathyroid suppressibility. Goldsmith RS; Furszyfer J; Johnson WJ; Fournier AE; Sizemore GW; Arnaud CD J Clin Invest; 1973 Jan; 52(1):173-80. PubMed ID: 4734166 [TBL] [Abstract][Full Text] [Related]
16. Hypercalcemia of malignancy: a study of clinical features and relationships among circulating levels of calcium, parathyroid hormone and parathyroid hormone-related peptide. Sriussadaporn S; Phoojaroenchanachai M; Ploybutr S; Plengvidhya N; Peerapatdit T; Nitiyanant W; Vannasaeng S; Vichayanrat A J Med Assoc Thai; 2007 Apr; 90(4):663-71. PubMed ID: 17487119 [TBL] [Abstract][Full Text] [Related]
17. Intravenous 1,25(OH)2D therapy increases the intact parathyroid hormone secretion set point in hemodialyzed patients. Brossard JH; Roy L; Lepage R; Gascon-Barré M; D'Amour P Miner Electrolyte Metab; 1997; 23(1):25-32. PubMed ID: 9058366 [TBL] [Abstract][Full Text] [Related]
18. [Chronic kidney disease (CKD) and bone. Management of chronic kidney disease-mineral and bone disorder in peritoneal dialysis patients]. Yaginuma T; Yamamoto H Clin Calcium; 2009 Apr; 19(4):508-13. PubMed ID: 19329829 [TBL] [Abstract][Full Text] [Related]
19. Influence of sevelamer on mineral metabolism and hyperparathyroidism in Japanese hemodialysis patients. Inoue T; Nagatoya K; Kagitani M; Shibahara N; Ueda H; Katsuoka Y; Ohashi S; Kitagawa Y; Nishimoto K; Yasuda H; Ther Apher Dial; 2007 Jun; 11(3):210-4. PubMed ID: 17498003 [TBL] [Abstract][Full Text] [Related]
20. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis. Ross EA; Tian J; Abboud H; Hippensteel R; Melnick JZ; Pradhan RS; Williams LA; Hamm LL; Sprague SM Am J Nephrol; 2008; 28(1):97-106. PubMed ID: 17914251 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]